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EDITORIAL  COMMENT
Many studies have shown that hyperhomocysteinemia
may be an independent risk factor for thromboembolic
disease. However, the results among studies and
populations have not been consistent. Furthermore,
the possible mechanisms of hyperhomocysteinemia in
vascular diseases are controversial. Mutations in the
MTHFR (5,10-methylenetetrahydrofolate reductase)
gene, resulting in rising levels of plasma homocysteine
or dietary folate, and vitamin B6 and B12 intake
deficiency, may play a role in this complicated process.
In this editorial comment, I discuss the metabolism of
homocysteine, hyperhomocysteinemia in vascular
diseases, and MTHFR deficiency (MTHFR gene
mutation) and/or nutritional deficiency and their
impact on thromboembolic diseases. Finally, based on
previous study results, the possible gene-nutrient
interactions in the pathophysiology of hyper-
homocysteinemia in thromboembolic diseases are
clarified.
Homocysteine, a sulfur-containing amino acid, is
an intermediate product in methionine metabolism.
Most of the dietary methionine is converted to
S-adenosylmethionine and then to S-adeno-
sylhomocysteine. Hydrolysis of S-adenosylhomo-
cysteine leads to adenosine and homocysteine.
Homocysteine may then be metabolized either
by transsulfuration or transmethylation, depend-
ing on the availability of methionine.1,2 Several fac-
tors are associated with the regulation of methionine
and homocysteine metabolism that depends on the
presence of adequate enzyme levels and their kinetic
properties. In general, plasma homocysteine levels
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increase with age in both genders; men have higher
plasma homocysteine levels than women. However,
both genetic and environmental factors play important
roles in this metabolic pathway. For genetic factors,
cystathionine beta-synthase (CBS) deficiency and
MTHFR deficiency are usually associated with elevated
plasma homocysteine levels. For environmental factors,
nutritional intake such as dietary deficiencies of folate,
vitamin B6 and B12 are associated with raised plasma
homocysteine concentrations. Riboflavin is one of the
cofactors for MTHFR that may be correlated with
high plasma homocysteine when it is deficient.3,4
Several studies have shown that excessively high
concentrations of plasma homocysteine may be
associated with premature vascular diseases and
thromboembolic vascular lesions. Plasma homocysteine
is considered to be an independent, graded and strong
risk factor for cardiovascular disease.5–10 Wilcken and
Wilcken11 first proposed the possible association
between plasma homocysteine level and vascular dis-
ease in 1976. Since then, many studies have shown
that high plasma homocysteine level is an independ-
ent predictor for the subsequent development of
cardiovascular disease.6,7 However, the mechanisms
behind the influence of high plasma homocysteine
on cardiovascular disease remain unclear. Plasma
homocysteine levels correlate negatively with plasma
folate, vitamin B6 and B12 levels that indicate in-
adequate dietary intake in patients with cardiovascular
disease. More interestingly, decreased activity of certain
enzymes involved in homocysteine metabolism could
also play a role in these patients. The thermolabile
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form of MTHFR is associated with impaired
homocysteine metabolism resulting in higher plasma
homocysteine levels and higher risk of developing
cardiovascular disease.3,12–14
MTHFR plays an important role in homocysteine
metabolism. It catalyzes the conversion of
5,10-methylenetetrahydrofolate to 5-methyl-
tetrahydrofolate. Deficiency of MTHFR is associated
with hyperhomocysteinemia and may be related
to neurologic abnormalities, mental retardation,
atherosclerosis and thrombosis.3,12–15 In 1995, Frosst
et al13 reported a thermolabile variant of MTHFR that
has a common 677 C-to-T mutation in MTHFR. The
thermolabile MTHFR enzyme activity was 17% in
patients with coronary heart disease and only 5% in
normal subjects. In 1996, Jacques et al3 measured
MTHFR activity and folate levels in 365 subjects and
found that those who were homozygous for C677T
had higher homocysteine and lower folate levels when
compared with those who had normal genotypes.
Guttormsen et al4 screened 18,043 subjects and found
that hyperhomocysteinemia was associated with low
plasma folate levels and with the thermolabile MTHFR
mutation. Sunder-Plassmann and Fodinger14 examined
several different gene polymorphisms, such as MTHFR,
GCP2,  RFC1 ,  and TCN2,  in homocysteine
metabolism. The most consistent effect on plasma
homocysteine levels was observed for the 677 C-to-T
mutation in MTHFR, whereas the other gene
polymorphisms had no major effect on plasma
homocysteine concentrations. Based on these studies,
although the main regulating enzymes of homocysteine
metabolism are CBS and MTHFR, the MTHFR 677
C-to-T mutation seems to play a more important role
in affecting plasma homocysteine levels.15
Apart from genetic factors, the dietary intake of
folate, vitamins B6 and B12 is also associated with
plasma homocysteine levels. For homocysteine
metabolism, vitamin B6 is a cofactor involved in CBS
metabolism, which metabolizes homocysteine. Folate
and vitamin B12 are cofactors involved in MTHFR
metabolism, another metabolic pathway to convert
homocysteine back to methionine. In the Framingham
Heart Study population, Selhub et al10 reported that
intake and blood levels of both folate and vitamin B6
were inversely related to plasma homocysteine level,
but for vitamin B12, only blood levels, not intake,
were associated with lower homocysteine, which may
be due to variation in absorption rather than to dietary
intake being the main determinant of vitamin B12
levels. Deficiencies in folate, vitamins B6 and B12
usually cause elevation of homocysteine levels, and
there is negative correlation with all of these vitamins,
even in subjects with normal vitamin levels. More
interestingly, a lower plasma vitamin level is associated
with a steeper rise in homocysteine levels.4
Many studies have evaluated MTHFR deficiency
(MTHFR gene mutation) and/or nutritional deficiency
in thromboembolic diseases. Meleady et al16 conducted
a case-controlled study of 711 patients with vascular
diseases and 747 controls to evaluate the effects of
MTHFR genotype, and plasma homocysteine and
folate levels on the risk of vascular disease. There was
a strong dose-response relationship between plasma
homocysteine level and vascular disease risk, and the
MTHFR genotype plays a key role in determining
plasma homocysteine concentration. However, the
vascular risk of the TT genotype (homozygotes for
the thermolabile mutation) was strengthened after
adjusting for conventional cardiovascular disease risk
factors but was attenuated after adjusting for plasma
homocysteine and folate levels. Further, there is
more evidence to suggest that MTHFR mutation is
only associated with plasma homocysteine levels but
not the risk of cardiovascular diseases in certain
populations.17–19 Brattstrom et al20 had similar findings
based on a meta-analysis of 23 studies, i.e. that MTHFR
gene mutation only leads to hyperhomocysteinemia
but not to vascular disease. However, in those studies,
dietary folate or vitamin B intakes were not fully
considered and may be potential confounders for
those populations with vascular disease and with low-
normal folate and/or vitamin B intakes.15 Rimm et al21
found that supplement and dietary intake of both
folic acid and vitamin B6 were associated with reduced
risk of coronary heart disease in the Nurses’ Heart
Study cohort.
These current data on mutation of the MTHFR
gene do not tell us the whole story of how hyper-
homocysteinemia plays a causal role in vascular dis-
ease. More complicated gene-nutrient interactions
indicate that not only MTHFR gene mutation but also
dietary intakes of folate and B vitamins play significant
roles in the occurrence of thromboembolic disease.
In this issue of the Journal of the Chinese Medical
Association, Ho et al22 examine 106 subjects with type
2 diabetes, deep vein thrombosis or coronary artery
disease to evaluate the influence of MTHFR C677T
polymorphism, and plasma folate, vitamin B6 and
B12 levels on thromboembolic disease in Chinese
patients. They found that MTHFR C677T poly-
morphism, vitamin B12 and triglyceride levels were
the most significant factors associated with plasma
homocysteine level. Patients with coronary heart disease
had higher plasma homocysteine levels than healthy
subjects and those with diabetes. These results are
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consistent with previous hypotheses and suggest that
a MTHFR TT homozygous genotype and vitamin
B12 level are important factors in the determination of
plasma homocysteine levels, and homocysteine levels
are associated with thromboembolic diseases. More
interestingly, in this study, the authors found that
plasma triglyceride had the greatest influence on plasma
homocysteine level in healthy subjects, coronary artery
disease patients, and all subjects together. Whether
these characteristics are only present in Chinese or are
related to special dietary intake needs further evaluation.
However, perhaps due to the small sample size in their
study, the authors did not examine the independent
effects of plasma homocysteine, folate, vitamins B6
and B12 levels and MTHFR polymorphism on differ-
ent disease states to determine which factor is the
most significant predictor on the development of
thromboembolic disease in Chinese. From their study,
homozygous MTHFR may play a role in higher plasma
homocysteine and the development of cardiovascular
end-points. Furthermore, the dietary intakes and plasma
levels of folate, vitamins B6 and B12 may also play
synergistic roles in cardiovascular disease occurrence.
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